Clostridium difficile infection resident survival guide: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
 
(46 intermediate revisions by 2 users not shown)
Line 25: Line 25:
|-
|-
| style="padding: 2px 10px; background: #4479BA; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |
| style="padding: 2px 10px; background: #4479BA; border-radius: 5px 5px 5px 5px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: 0 1px 1px rgba(0, 0, 0, 0.5);" |
[[{{PAGENAME}}#Guidelines|{{fontcolor|#F8F8FF|Guidelines}}]]
[[{{PAGENAME}}#Guidelines and Resources|{{fontcolor|#F8F8FF|Guidelines and Resources}}]]
|}
|}
__NOTOC__
__NOTOC____NOEDITSECTION__
{{Main|Clostridium difficile infection}}
{{Main|Clostridium difficile infection}}
{{CMG}}
{{CMG}}; Gerald Chi, M.D.


==Overview==  
==Overview==  
Line 49: Line 49:


Diagnostic tests for ''[[C. difficile]]'' infection include:<ref>{{Cite journal| doi = 10.1111/1469-0691.12418| issn = 1469-0691| volume = 20 Suppl 2| pages = 1–26| last1 = Debast| first1 = S. B.| last2 = Bauer| first2 = M. P.| last3 = Kuijper| first3 = E. J.| last4 = European Society of Clinical Microbiology and Infectious Diseases| title = European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection| journal = Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases| date = 2014-03| pmid = 24118601}}</ref>
Diagnostic tests for ''[[C. difficile]]'' infection include:<ref>{{Cite journal| doi = 10.1111/1469-0691.12418| issn = 1469-0691| volume = 20 Suppl 2| pages = 1–26| last1 = Debast| first1 = S. B.| last2 = Bauer| first2 = M. P.| last3 = Kuijper| first3 = E. J.| last4 = European Society of Clinical Microbiology and Infectious Diseases| title = European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection| journal = Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases| date = 2014-03| pmid = 24118601}}</ref>
* [[Enzyme immunoassay|Enzyme immunoassay (EIA)]]: [[GDH|glutamate dehydrogenase (GDH)]], toxins A and B
* [[Enzyme immunoassay|Enzyme immunoassay (EIA)]]: [[GDH|glutamate dehydrogenase (GDH)]], [[toxins]] A and B
* Nucleic acid amplification tests (NAAT): [[16S ribosomal RNA]], [[GDH]] genes, toxin genes
* Nucleic acid amplification tests (NAAT): [[16S ribosomal RNA]], [[GDH]] genes, [[toxin]] genes
* Cell culture cytoxicity assay (CCA)
* Cell culture cytoxicity assay (CCA)
* Culture of toxigenic ''[[C. difficile]]''
* Culture of toxigenic ''[[C. difficile]]''


==Classification of Disease Severity==
==Classification of Disease Severity==
===American College of Gastroenterology (ACG)===
Classification of disease severity:<ref>{{Cite journal| doi = 10.1038/ajg.2013.4| issn = 1572-0241| volume = 108| issue = 4| pages = 478–498; quiz 499| last1 = Surawicz| first1 = Christina M.| last2 = Brandt| first2 = Lawrence J.| last3 = Binion| first3 = David G.| last4 = Ananthakrishnan| first4 = Ashwin N.| last5 = Curry| first5 = Scott R.| last6 = Gilligan| first6 = Peter H.| last7 = McFarland| first7 = Lynne V.| last8 = Mellow| first8 = Mark| last9 = Zuckerbraun| first9 = Brian S.| title = Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections| journal = The American Journal of Gastroenterology| date = 2013-04| pmid = 23439232}}</ref>
* '''Mild disease'''
: [[Diarrhea]] as the only symptom
* '''Moderate disease'''
: [[Diarrhea]] but without additional symptoms/signs meeting the definition of severe or complicated disease
* '''Severe disease'''
: [[Hypoalbuminemia]] (serum [[albumin]] < 3 g/dl) {{and}}
: [[WBC]] ≥ 15,000 cells/mL {{or}} [[abdominal tenderness]] without criteria of complicated disease
* '''Complicated disease'''
: Any of the following attributable to ''[[C. difficile]]'' infection:
: Admission to [[intensive care unit]]
: [[Hypotension]] with or without required use of [[vasopressors]]
: [[Fever]] ≥ 38.5°C
: [[Ileus]] (acute [[nausea]], [[emesis]], sudden cessation of [[diarrhea]], significant [[abdominal distention]], or radiological signs consistent with disturbed intestinal transit)
: [[Altered mental status|Mental status changes]]
: [[WBC]] ≥ 35,000 cells/mL or < 2,000 cells/mL
: Serum [[lactate]] levels > 2.2 mmol/l
: Any evidence of end organ failure
* '''Recurrent disease'''
: Recurrence within 8 weeks of completion of therapy


===Infectious Disease Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)===
===Infectious Disease Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)===
Line 70: Line 96:
'''Severe disease''' is defined as an episode of ''[[C. difficile]]'' infection with:<ref>{{Cite journal| doi = 10.1111/1469-0691.12418| issn = 1469-0691| volume = 20 Suppl 2| pages = 1–26| last1 = Debast| first1 = S. B.| last2 = Bauer| first2 = M. P.| last3 = Kuijper| first3 = E. J.| last4 = European Society of Clinical Microbiology and Infectious Diseases| title = European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection| journal = Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases| date = 2014-03| pmid = 24118601}}</ref>
'''Severe disease''' is defined as an episode of ''[[C. difficile]]'' infection with:<ref>{{Cite journal| doi = 10.1111/1469-0691.12418| issn = 1469-0691| volume = 20 Suppl 2| pages = 1–26| last1 = Debast| first1 = S. B.| last2 = Bauer| first2 = M. P.| last3 = Kuijper| first3 = E. J.| last4 = European Society of Clinical Microbiology and Infectious Diseases| title = European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection| journal = Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases| date = 2014-03| pmid = 24118601}}</ref>
* One or more specific signs and symptoms of severe [[colitis]] {{or2}}
* One or more specific signs and symptoms of severe [[colitis]] {{or2}}
* A complicated course of disease, with significant systemic [[toxin]] effects and [[shock]], resulting in need for [[ICU]] admission, [[colectomy]], or death.
* A complicated course of disease, with significant systemic [[toxin]] effects and [[shock]], resulting in need for [[ICU|intensive care unit]] admission, [[colectomy]], or death.


Characteristics that correlate with severity of [[colitis]]:<ref>{{Cite journal| doi = 10.1111/1469-0691.12418| issn = 1469-0691| volume = 20 Suppl 2| pages = 1–26| last1 = Debast| first1 = S. B.| last2 = Bauer| first2 = M. P.| last3 = Kuijper| first3 = E. J.| last4 = European Society of Clinical Microbiology and Infectious Diseases| title = European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection| journal = Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases| date = 2014-03| pmid = 24118601}}</ref>
Characteristics that correlate with severity of [[colitis]]:<ref>{{Cite journal| doi = 10.1111/1469-0691.12418| issn = 1469-0691| volume = 20 Suppl 2| pages = 1–26| last1 = Debast| first1 = S. B.| last2 = Bauer| first2 = M. P.| last3 = Kuijper| first3 = E. J.| last4 = European Society of Clinical Microbiology and Infectious Diseases| title = European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection| journal = Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases| date = 2014-03| pmid = 24118601}}</ref>
Line 95: Line 121:
: Pericolonic fat stranding
: Pericolonic fat stranding
: [[Ascites]] not explained by other causes
: [[Ascites]] not explained by other causes
===American College of Gastroenterology (ACG)===
Classification of disease severity:<ref>{{Cite journal| doi = 10.1038/ajg.2013.4| issn = 1572-0241| volume = 108| issue = 4| pages = 478–498; quiz 499| last1 = Surawicz| first1 = Christina M.| last2 = Brandt| first2 = Lawrence J.| last3 = Binion| first3 = David G.| last4 = Ananthakrishnan| first4 = Ashwin N.| last5 = Curry| first5 = Scott R.| last6 = Gilligan| first6 = Peter H.| last7 = McFarland| first7 = Lynne V.| last8 = Mellow| first8 = Mark| last9 = Zuckerbraun| first9 = Brian S.| title = Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections| journal = The American Journal of Gastroenterology| date = 2013-04| pmid = 23439232}}</ref>
* '''Mild disease'''
: [[Diarrhea]] as the only symptom
* '''Moderate disease'''
: [[Diarrhea]] but without additional symptoms/signs meeting the definition of severe or complicated disease
* '''Severe disease'''
: [[Hypoalbuminemia]] (serum [[albumin]] < 3 g/dl) {{and}}
: [[WBC]] ≥ 15,000 cells/mL {{or}} [[abdominal tenderness]] without criteria of complicated disease
* '''Complicated disease'''
: Any of the following attributable to ''C. difficile'' infection:
: Admission to intensive care unit
: Hypotension with or without required use of vasopressors
: Fever ≥ 38.5°C
: Ileus (acute nausea, emesis, sudden cessation of diarrhea, significant abdominal distention, or radiological signs consistent with disturbed intestinal transit)
: Mental status changes
: WBC ≥ 35,000 cells/mL or < 2,000 cells/mL
: Serum lactate levels > 2.2 mmol/l
: Any evidence of end organ failure
* '''Recurrent disease'''
: Recurrence within 8 weeks of completion of therapy


==Risk Factors==
==Risk Factors==
The most important risk factor remains antibiotic use.  Other established risk factors include:<ref>{{Cite journal| doi = 10.1016/j.mayocp.2012.07.016| issn = 1942-5546| volume = 87| issue = 11| pages = 1106–1117| last1 = Khanna| first1 = Sahil| last2 = Pardi| first2 = Darrell S.| title = Clostridium difficile infection: new insights into management| journal = Mayo Clinic Proceedings| date = 2012-11| pmid = 23127735| pmc = PMC3541870}}</ref>
The most important risk factor remains [[antibiotic|antibiotic use]].  Other established risk factors include:<ref>{{Cite journal| doi = 10.1016/j.mayocp.2012.07.016| issn = 1942-5546| volume = 87| issue = 11| pages = 1106–1117| last1 = Khanna| first1 = Sahil| last2 = Pardi| first2 = Darrell S.| title = Clostridium difficile infection: new insights into management| journal = Mayo Clinic Proceedings| date = 2012-11| pmid = 23127735| pmc = PMC3541870}}</ref>
* Advanced age
* [[Elderly|Advanced age]]
* Chemotherapy
* [[Chemotherapy]]
* Chronic kidney disease
* [[Chronic kidney disease]]
* Consumption of processed meat
* Consumption of processed meat
* Contact with active carriers
* Contact with active carriers
* Cystic fibrosis
* [[Cystic fibrosis]]
* Diabetes mellitus
* [[Diabetes mellitus]]
* Hypoalbuminemia
* [[Hypoalbuminemia]]
* Immunosuppression, immunodeficiency, or human immunodeficiency virus
* [[Immunosuppression]], [[immunodeficiency]], or [[human immunodeficiency virus]]
* Increased risk with prolonged use or multiple antibiotics
* Increased risk with prolonged use or multiple [[antibiotics]]
* Inflammatory bowel disease
* [[Inflammatory bowel disease]]
* Liver cirrhosis
* [[Liver cirrhosis]]
* Malignancy
* [[Malignancy]]
* Malnutrition
* [[Malnutrition]]
* Nursing home or long-term care facility residence
* Nursing home or long-term care facility residence
* Presence of comorbid conditions
* Presence of comorbid conditions
* Presence of gastrostomy or jejunostomy tube
* Presence of [[gastrostomy]] or [[Feeding tube#Jejunal feeding tube|jejunostomy tube]]
* Previous gastrointestinal surgery or endoscopic procedure
* Previous [[gastrointestinal]] [[surgery]] or [[endoscopic]] procedure
* Previous hospitalization and prolonged length of hospital stay
* Previous hospitalization and prolonged length of hospital stay
* Solid organ or hematopoietic stem cell transplantation
* Solid organ or [[hematopoietic stem cell transplantation]]
* Use of proton pump inhibitors
* Use of [[proton pump inhibitor]]s


Use of the following antibiotics has been associated with ''C. difficile'' infection:<ref>{{Cite journal| doi = 10.1056/NEJMra1403772| issn = 1533-4406| volume = 372| issue = 16| pages = 1539–1548| last1 = Leffler| first1 = Daniel A.| last2 = Lamont| first2 = J. Thomas| title = Clostridium difficile infection| journal = The New England Journal of Medicine| date = 2015-04-16| pmid = 25875259}}</ref>
Use of the following [[antibiotics]] has been associated with ''[[C. difficile]]'' infection:<ref>{{Cite journal| doi = 10.1056/NEJMra1403772| issn = 1533-4406| volume = 372| issue = 16| pages = 1539–1548| last1 = Leffler| first1 = Daniel A.| last2 = Lamont| first2 = J. Thomas| title = Clostridium difficile infection| journal = The New England Journal of Medicine| date = 2015-04-16| pmid = 25875259}}</ref>
* '''Very common'''
* '''Very common'''
: [[Clindamycin]]
: [[Clindamycin]]
Line 192: Line 192:
{{Familytree|boxstyle=width: 700px; text-align: left; font-size: 100%; padding: 0px;| A01 | | |A01=<div style="padding: 0px 10px;">
{{Familytree|boxstyle=width: 700px; text-align: left; font-size: 100%; padding: 0px;| A01 | | |A01=<div style="padding: 0px 10px;">
==''Clostridium difficile'' Infection==
==''Clostridium difficile'' Infection==
* Diarrhea (passage of 3 or more unformed stools in ≤ 24 hours) with microbiological evidence of ''C. difficile''
* [[Diarrhea]] (passage of 3 or more unformed stools in ≤ 24 hours) with microbiological evidence of ''[[C. difficile]]''
* Colonoscopic or histopathological findings demonstrating pseudomembranous colitis
* [[Colonoscopic]] or histopathological findings demonstrating pseudomembranous colitis
</div>}}
</div>}}
{{Familytree|boxstyle=width: 700px; text-align: left; font-size: 100%; padding: 0px;| |!| | | |}}
{{Familytree|boxstyle=width: 700px; text-align: left; font-size: 100%; padding: 0px;| |!| | | |}}
Line 199: Line 199:
==Focused History==
==Focused History==
* Characterize the symptoms:
* Characterize the symptoms:
:* Abdominal discomfort
:* [[Abdominal discomfort]]
:* Poor appetite
:* [[Poor appetite]]
:* Diarrhea
:* [[Diarrhea]]
:* Nausea
:* [[Nausea]]
:* Vomiting
:* [[Vomiting]]
:* Bloating
:* [[Bloating]]
:* Belching
:* [[Belching]]
:* Flatulence
:* [[Flatulence]]
:* Lack of bowel movement
:* [[Constipation]] or [[obstipation]]
* Other relevant history:
* Other relevant history:
:* [[{{PAGENAME}}#Risk Factors|Risk factors]]
:* Risk factors ([[{{PAGENAME}}#Risk Factors|details]])
:* Comorbidities
:* Comorbidities
:* Recent sick contacts
:* Recent sick contacts
:* Recent hospitalizations
:* Recent hospitalizations
:* Prior use of antibiotics
:* Prior use of [[antibiotics]]
:* Immunosuppressive state
:* [[Immunosuppressive state]]
:* Travel history
:* Travel history
</div>}}
</div>}}
Line 220: Line 220:
{{Familytree|boxstyle=width: 700px; text-align: left; font-size: 100%; padding: 0px;| A01 | | |A01=<div style="padding: 0px 10px;">
{{Familytree|boxstyle=width: 700px; text-align: left; font-size: 100%; padding: 0px;| A01 | | |A01=<div style="padding: 0px 10px;">
==Physical Examination==
==Physical Examination==
* Vital signs (body temperature, pulse rate, respiration rate, blood pressure)
* Vital signs ([[body temperature]], [[pulse rate]], [[respiration rate]], [[blood pressure]])
* Signs of ileus (distended and tympanic abdomen with tenderness, hypoactive bowel sounds)
* Signs of [[ileus]] ([[abdominal distention|distended and tympanic abdomen]] with [[tenderness]], [[bowel sounds|hypoactive bowel sounds]])
* Signs of peritonitis (rebound tenderness, abdominal wall rigidity, hypoactive bowel sounds)
* Signs of [[peritonitis]] ([[rebound tenderness]], [[abdominal guarding]], [[bowel sounds|hypoactive bowel sounds]])
* Signs of dehydration (delayed capillary refill, decreased skin turgor, abnormal respiratory pattern)
* Signs of [[dehydration]] ([[capillary refill|delayed capillary refill]], [[dehydration|decreased skin turgor]], abnormal respiratory pattern)
* Signs of respiratory distress (tachypnea, tachycardia, abnormal breath sounds)
* Signs of [[respiratory distress]] ([[tachypnea]], [[tachycardia]], abnormal [[breath sounds]])
* Signs of multiple organ failure (cool and clammy skin, tissue hypoperfusion)
* Signs of [[shock|multiple organ failure]] ([[cold and clammy skin]], [[shock|tissue hypoperfusion]])
</div>}}
</div>}}
{{Familytree|boxstyle=width: 700px; text-align: left; font-size: 100%; padding: 0px;| |!| | | |}}
{{Familytree|boxstyle=width: 700px; text-align: left; font-size: 100%; padding: 0px;| |!| | | |}}
Line 233: Line 233:
* [[Basic metabolic panel|Basic metabolic panel including urea nitrogen and creatinine]]
* [[Basic metabolic panel|Basic metabolic panel including urea nitrogen and creatinine]]
* [[AST]], [[ALT]], [[bilirubin]], [[alkaline phosphatase]], [[albumin]], [[lactate]]
* [[AST]], [[ALT]], [[bilirubin]], [[alkaline phosphatase]], [[albumin]], [[lactate]]
* Consider abdominal CT scan or colonoscopy in severe disease or concurrent IBD
* Consider abdominal [[CT scan]] or [[colonoscopy]] in severe disease or concurrent [[inflammatory bowel disease]]
</div>}}
</div>}}
{{Familytree|boxstyle=width: 700px; text-align: left; font-size: 100%; padding: 0px;| |!| | | |}}
{{Familytree|boxstyle=width: 700px; text-align: left; font-size: 100%; padding: 0px;| |!| | | |}}
{{Familytree|boxstyle=width: 700px; text-align: left; font-size: 100%; padding: 0px;| A01 | | |A01=<div style="padding: 0px 10px;">
{{Familytree|boxstyle=width: 700px; text-align: left; font-size: 100%; padding: 0px;| A01 | | |A01=<div style="padding: 0px 10px;">
==Other Investigation==
==Other Investigation==
Positive results of either EIA or NAAT should prompt treatment.
Positive results of either [[EIA]] or [[NAAT]] should prompt treatment.
* GDH (high sensitivity, low specificity): screening test
* [[GDH]] (high sensitivity, low specificity): screening test
* EIA for toxins (low sensitivity, high specificity): confirmatory test
* [[EIA]] for toxins (low sensitivity, high specificity): confirmatory test
* NAAT (high sensitivity, high specificity): standard diagnostic test
* [[NAAT]] (high sensitivity, high specificity): standard diagnostic test
</div>}}
</div>}}
{{Familytree/end}}
{{Familytree/end}}
Line 252: Line 252:


===Mild disease===
===Mild disease===
* Predisposing antibiotic cessation
* Predisposing [[antibiotic]] cessation {{and}}
* Hydration
* [[Hydration]] {{and}}
* Monitoring of clinical status
* Monitoring of clinical status {{and}}
* Administration of metronidazole (500 mg three times per day) {{or2}}
* Administration of [[metronidazole]] (500 mg three times per day) {{or2}}
: Close outpatient monitoring without the administration of antibiotics
: Close outpatient monitoring without the administration of [[antibiotics]]


===Moderate disease===
===Moderate disease===
* Consideration of hospitalization
* Consideration of hospitalization {{and}}
* Cessation of predisposing antibiotics
* Cessation of predisposing [[antibiotics]] {{and}}
* Hydration
* [[Hydration]] {{and}}
* Monitoring of clinical status
* Monitoring of clinical status {{and}}
* Administration of metronidazole (500 mg three times per day) {{or2}}
* Administration of [[metronidazole]] (500 mg three times per day) {{or2}}
: Administration of vancomycin (125 mg orally four times per day for 14 days)
: Administration of [[vancomycin]] (125 mg orally four times per day for 14 days)


===Severe disease===
===Severe disease===
* Hospitalization
* Hospitalization {{and}}
* Oral or nasogastric vancomycin (500 mg four times per day) with or without intravenous metronidazole (500 mg three times per day) {{or2}}
* Oral or nasogastric [[vancomycin]] (500 mg four times per day) with or without intravenous [[metronidazole]] (500 mg three times per day) {{or2}}
: Oral fidaxomicin (200 mg twice a day for 10 days) if the risk of recurrence is high
: Oral [[fidaxomicin]] (200 mg twice a day for 10 days) if the risk of recurrence is high


===Complicated disease===
===Complicated disease===
* Antibiotics as for severe infection
* [[Antibiotics]] as for severe infection {{and}}
* Surgical consultation for subtotal colectomy or a diverting ileostomy with vancomycin colonic lavage
* Surgical consultation for subtotal [[colectomy]] or a diverting [[ileostomy]] with [[vancomycin]] colonic lavage {{and}}
* Consideration of fecal microbial transplantation or additional antibiotics
* Consideration of [[fecal microbial transplantation]] or additional [[antibiotics]]


===First recurrence===
===First recurrence===
* Oral vancomycin (125 mg four times per day for 14 days) {{or2}}
* Oral [[vancomycin]] (125 mg four times per day for 14 days) {{or2}}
: Oral fidaxomicin (200 mg twice a day for 10 days)
: Oral [[fidaxomicin]] (200 mg twice a day for 10 days)


===Second or further recurrence===
===Second or further recurrence===
* Vancomycin in a tapered and pulsed regimen {{or2}}
* [[Vancomycin]] in a tapered and pulsed regimen<sup>†</sup> {{or2}}
* Fecal microbial transplantation {{or2}}
* [[Fecal microbial transplantation]] {{or2}}
* Fidaxomicin (200 mg twice a day for 10 days)<ref>{{Cite journal| doi = 10.1056/NEJMra1403772| issn = 1533-4406| volume = 372| issue = 16| pages = 1539–1548| last1 = Leffler| first1 = Daniel A.| last2 = Lamont| first2 = J. Thomas| title = Clostridium difficile infection| journal = The New England Journal of Medicine| date = 2015-04-16| pmid = 25875259}}</ref>
* [[Fidaxomicin]] (200 mg twice a day for 10 days)<ref>{{Cite journal| doi = 10.1056/NEJMra1403772| issn = 1533-4406| volume = 372| issue = 16| pages = 1539–1548| last1 = Leffler| first1 = Daniel A.| last2 = Lamont| first2 = J. Thomas| title = Clostridium difficile infection| journal = The New England Journal of Medicine| date = 2015-04-16| pmid = 25875259}}</ref> <BR><div style=text-indent: 20px;"><sup>†</sup>125 mg qid x 1 week, 125 mg tid x 1 week, 125 mg bid x 1 week, 125 mg qd x 1 week, 125 mg qod x 1 week, then 125 mg every 3 days x 1 week.</div>


==Dos and Don'ts==
==Dos and Don'ts==


===Dos===
===Dos===
* Inform the laboratory when testing for ''Clostridium difficile'' from formed stools in a patient with ileus.
* Liaise with microbiology service when testing for ''[[Clostridium difficile]]'' from formed stools in a patient with [[ileus]].
* Initiate empiric antibiotics regardless of the laboratory results when there is a high index of suspicion for ''C. difficile'' infection.
* Initiate empiric [[antibiotics]] regardless of the laboratory results when there is a high index of suspicion for ''[[C. difficile]]'' infection.
* Vancomycin should be delivered via enema to treat patients in whom oral antibiotics cannot reach a segment of the colon as in Hartman’s pouch, ileostomy, or colonic diversion.
* [[Vancomycin]] should be delivered via [[enema]] to treat patients in whom oral [[antibiotics]] cannot reach a segment of the colon as in [[Hartmann's operation|Hartmann's pouch]], [[ileostomy]], or [[Bowel resection|colonic diversion]].
* Test for ''C. difficile'' among patients with diarrhea in the context of malignancy, chemotherapy, immunosuppressive therapy, organ transplantation, cirrhosis, inflammatory bowel disease, or pregnancy.
* Test for ''[[C. difficile]]'' among patients with diarrhea in the context of [[malignancy]], [[chemotherapy]], [[immunosuppressive therapy]], [[organ transplantation]], [[cirrhosis]], [[inflammatory bowel disease]], or [[pregnancy]].


===Don'ts===
===Don'ts===
* Do NOT test for ''C. difficile'' in a patient without diarrhea.
* Do NOT test for ''[[C. difficile]]'' in a patient without [[diarrhea]].
* Do NOT repeat test if the results are negative.
* Do NOT repeat test if the results are negative.
* Do NOT perform test of microbiological cure.
* Do NOT perform test of microbiological cure.
* Do NOT treat asymptomatic carriage.
* Do NOT treat asymptomatic carriage.
* Do NOT administer antiperistaltic agents to patients with suspected or confirmed ''C. difficile'' infection.
* Do NOT administer [[peristalsis|antiperistaltic agent]]s to patients with suspected or confirmed ''[[C. difficile]]'' infection.


==Guidelines==
==Guidelines and Resources==


===Infectious Disease Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)===
===Infectious Disease Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)===
Line 329: Line 329:
[[Category:Disease]]
[[Category:Disease]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Infectious disease]]
 
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Resident survival guide]]
[[Category:Resident survival guide]]

Latest revision as of 17:26, 18 September 2017

Clostridium difficile infection

Overview

Diagnostic Criteria

Classification of Disease Severity

Risk Factors

Complete Diagnostic Approach

Management

Dos and Don'ts

Guidelines and Resources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Gerald Chi, M.D.

Overview

Clostridium difficile infection is the leading cause to nosocomial diarrhea. Clinical presentation ranges across a broad spectrum from asymptomatic carriage, to diarrheal illness, to complicated disease hallmarked by pseudomembranous colitis, toxic megacolon, or bowel perforation. Diagnosis is established by the presence of diarrheal symptoms coupled with positive stool tests or endoscopic findings. Therapeutic approach and antibiotic choice should be stratified according to severity of disease and risk of recurrence.

Diagnostic Criteria

Infectious Disease Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

The diagnosis of C. difficile infection should be based on a combination of clinical and laboratory findings. A case definition for the usual presentation includes the following findings:[1]

  • The presence of diarrhea, defined as passage of 3 or more unformed stools in 24 or fewer consecutive hours AND
  • A stool test result positive for the presence of toxigenic C. difficile or its toxins OR colonoscopic or histopathologic findings demonstrating pseudomembranous colitis.

The same criteria should be used to diagnose recurrent C. difficile infection.

European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Diagnosis of C. difficile infection is based on the following criteria:[2]

  • A combination of signs and symptoms, confirmed by microbiological evidence of C. difficile in stools, in the absence of another cause
    OR
  • Colonoscopic or histopathological findings demonstrating pseudomembranous colitis

Diagnostic tests for C. difficile infection include:[3]

Classification of Disease Severity

American College of Gastroenterology (ACG)

Classification of disease severity:[4]

  • Mild disease
Diarrhea as the only symptom
  • Moderate disease
Diarrhea but without additional symptoms/signs meeting the definition of severe or complicated disease
  • Severe disease
Hypoalbuminemia (serum albumin < 3 g/dl) AND
WBC ≥ 15,000 cells/mL OR abdominal tenderness without criteria of complicated disease
  • Complicated disease
Any of the following attributable to C. difficile infection:
Admission to intensive care unit
Hypotension with or without required use of vasopressors
Fever ≥ 38.5°C
Ileus (acute nausea, emesis, sudden cessation of diarrhea, significant abdominal distention, or radiological signs consistent with disturbed intestinal transit)
Mental status changes
WBC ≥ 35,000 cells/mL or < 2,000 cells/mL
Serum lactate levels > 2.2 mmol/l
Any evidence of end organ failure
  • Recurrent disease
Recurrence within 8 weeks of completion of therapy

Infectious Disease Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

Initial episode of C. difficile infection may be stratified by disease severity as follows:[5]

  • Mild-to-moderate disease
Leukocytosis with WBC < 15,000 cells/mL AND serum creatinine < 1.5 times the premorbid level
  • Severe disease
Leukocytosis with WBC ≥ 15,000 cells/mL OR serum creatinine ≥ 1.5 times the premorbid level
  • Severe, complicated disease
Hypotension or shock, ileus, megacolon

European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Severe disease is defined as an episode of C. difficile infection with:[6]

Characteristics that correlate with severity of colitis:[7]

  • Physical examination
Fever (core body temperature > 38.5°C)
Rigors (uncontrollable shaking and a feeling of cold followed by a rise in body temperature)
Hemodynamic instability including signs of distributive shock
Respiratory failure requiring mechanical ventilation
Signs and symptoms of peritonitis
Signs and symptoms of colonic ileus
  • Laboratory investigations
Marked leukocytosis (leukocyte count > 15,000 cells/mL)
Marked left shift (band neutrophils > 20% of leukocytes)
Rise in serum creatinine (> 50% above the baseline)
Elevated serum lactate (≥ 5 mmol/L)
Markedly reduced serum albumin (< 3 mg/dl)
Pseudomembranous colitis
  • Imaging
Distention of large intestine (> 6 cm in transverse width of colon)
Colonic wall thickening including low-attenuation mural thickening
Pericolonic fat stranding
Ascites not explained by other causes

Risk Factors

The most important risk factor remains antibiotic use. Other established risk factors include:[8]

Use of the following antibiotics has been associated with C. difficile infection:[9]

  • Very common
Clindamycin
Ampicillin
Amoxicillin
Cephalosporins
Fluoroquinolones
  • Somewhat common
Penicillins
Sulfonamides
Trimethoprim
Trimethoprim-Sulfamethoxazole
Macrolides
  • Uncommon
Aminoglycosides
Bacitracin
Metronidazole
Teicoplanin
Rifampin
Chloramphenicol
Tetracyclines
Carbapenems
Daptomycin
Tigecycline

Complete Diagnostic Approach

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBC, complete blood count; DC, differential count; EIA, enzyme immunoassay; GDH, glutamate dehydrogenase; NAAT, nucleic acid amplification test; PCR, polymerase chain reaction; SMA-7, sequential multiple analysis-7.

Clostridium difficile Infection

  • Diarrhea (passage of 3 or more unformed stools in ≤ 24 hours) with microbiological evidence of C. difficile
  • Colonoscopic or histopathological findings demonstrating pseudomembranous colitis
 
 
 
 
 
 
 
 

Focused History

  • Characterize the symptoms:
  • Other relevant history:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Other Investigation

Positive results of either EIA or NAAT should prompt treatment.

  • GDH (high sensitivity, low specificity): screening test
  • EIA for toxins (low sensitivity, high specificity): confirmatory test
  • NAAT (high sensitivity, high specificity): standard diagnostic test
 
 

Management

Asymptomatic carrier

  • No treatment indicated

Mild disease

Close outpatient monitoring without the administration of antibiotics

Moderate disease

  • Consideration of hospitalization AND
  • Cessation of predisposing antibiotics AND
  • Hydration AND
  • Monitoring of clinical status AND
  • Administration of metronidazole (500 mg three times per day)
    OR
Administration of vancomycin (125 mg orally four times per day for 14 days)

Severe disease

  • Hospitalization AND
  • Oral or nasogastric vancomycin (500 mg four times per day) with or without intravenous metronidazole (500 mg three times per day)
    OR
Oral fidaxomicin (200 mg twice a day for 10 days) if the risk of recurrence is high

Complicated disease

First recurrence

  • Oral vancomycin (125 mg four times per day for 14 days)
    OR
Oral fidaxomicin (200 mg twice a day for 10 days)

Second or further recurrence

Dos and Don'ts

Dos

Don'ts

  • Do NOT test for C. difficile in a patient without diarrhea.
  • Do NOT repeat test if the results are negative.
  • Do NOT perform test of microbiological cure.
  • Do NOT treat asymptomatic carriage.
  • Do NOT administer antiperistaltic agents to patients with suspected or confirmed C. difficile infection.

Guidelines and Resources

Infectious Disease Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

  • Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals (2014)[11]
  • Clinical Practice Guidelines for Clostridium difficile Infection in Adults (2010)[12]

American College of Gastroenterology (ACG)

  • Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections (2013)[13]

Association for Professionals in Infection Control and Epidemiology (APIC)

  • Preventing Clostridium difficile infections (2011)[14]

Eastern Association for the Surgery of Trauma (EAST)

  • Timing and type of surgical treatment of Clostridium difficile-associated disease (2014)[15]

American Society of Colon and Rectal Surgeons (ASCRS)

  • Practice Parameters for the Management of Clostridium difficile Infection (2015)[16]

European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

  • Update of the Treatment Guidance Document for Clostridium difficile Infection (2014)[17]

American Academy of Pediatrics (AAP)

  • Policy Statement: Clostridium difficile Infection in Infants and Children (2013)[18]

References

  1. Cohen, Stuart H.; Gerding, Dale N.; Johnson, Stuart; Kelly, Ciaran P.; Loo, Vivian G.; McDonald, L. Clifford; Pepin, Jacques; Wilcox, Mark H.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America (2010-05). "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)". Infection Control and Hospital Epidemiology. 31 (5): 431–455. doi:10.1086/651706. ISSN 1559-6834. PMID 20307191. Check date values in: |date= (help)
  2. Debast, S. B.; Bauer, M. P.; Kuijper, E. J.; European Society of Clinical Microbiology and Infectious Diseases (2014-03). "European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection". Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 20 Suppl 2: 1–26. doi:10.1111/1469-0691.12418. ISSN 1469-0691. PMID 24118601. Check date values in: |date= (help)
  3. Debast, S. B.; Bauer, M. P.; Kuijper, E. J.; European Society of Clinical Microbiology and Infectious Diseases (2014-03). "European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection". Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 20 Suppl 2: 1–26. doi:10.1111/1469-0691.12418. ISSN 1469-0691. PMID 24118601. Check date values in: |date= (help)
  4. Surawicz, Christina M.; Brandt, Lawrence J.; Binion, David G.; Ananthakrishnan, Ashwin N.; Curry, Scott R.; Gilligan, Peter H.; McFarland, Lynne V.; Mellow, Mark; Zuckerbraun, Brian S. (2013-04). "Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections". The American Journal of Gastroenterology. 108 (4): 478–498, quiz 499. doi:10.1038/ajg.2013.4. ISSN 1572-0241. PMID 23439232. Check date values in: |date= (help)
  5. Cohen, Stuart H.; Gerding, Dale N.; Johnson, Stuart; Kelly, Ciaran P.; Loo, Vivian G.; McDonald, L. Clifford; Pepin, Jacques; Wilcox, Mark H.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America (2010-05). "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)". Infection Control and Hospital Epidemiology. 31 (5): 431–455. doi:10.1086/651706. ISSN 1559-6834. PMID 20307191. Check date values in: |date= (help)
  6. Debast, S. B.; Bauer, M. P.; Kuijper, E. J.; European Society of Clinical Microbiology and Infectious Diseases (2014-03). "European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection". Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 20 Suppl 2: 1–26. doi:10.1111/1469-0691.12418. ISSN 1469-0691. PMID 24118601. Check date values in: |date= (help)
  7. Debast, S. B.; Bauer, M. P.; Kuijper, E. J.; European Society of Clinical Microbiology and Infectious Diseases (2014-03). "European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection". Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 20 Suppl 2: 1–26. doi:10.1111/1469-0691.12418. ISSN 1469-0691. PMID 24118601. Check date values in: |date= (help)
  8. Khanna, Sahil; Pardi, Darrell S. (2012-11). "Clostridium difficile infection: new insights into management". Mayo Clinic Proceedings. 87 (11): 1106–1117. doi:10.1016/j.mayocp.2012.07.016. ISSN 1942-5546. PMC 3541870. PMID 23127735. Check date values in: |date= (help)
  9. Leffler, Daniel A.; Lamont, J. Thomas (2015-04-16). "Clostridium difficile infection". The New England Journal of Medicine. 372 (16): 1539–1548. doi:10.1056/NEJMra1403772. ISSN 1533-4406. PMID 25875259.
  10. Leffler, Daniel A.; Lamont, J. Thomas (2015-04-16). "Clostridium difficile infection". The New England Journal of Medicine. 372 (16): 1539–1548. doi:10.1056/NEJMra1403772. ISSN 1533-4406. PMID 25875259.
  11. Dubberke, Erik R.; Carling, Philip; Carrico, Ruth; Donskey, Curtis J.; Loo, Vivian G.; McDonald, L. Clifford; Maragakis, Lisa L.; Sandora, Thomas J.; Weber, David J.; Yokoe, Deborah S.; Gerding, Dale N. (2014-09). "Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update". Infection Control and Hospital Epidemiology. 35 Suppl 2: –48-65. ISSN 1559-6834. PMID 25376069. Check date values in: |date= (help)
  12. Cohen, Stuart H.; Gerding, Dale N.; Johnson, Stuart; Kelly, Ciaran P.; Loo, Vivian G.; McDonald, L. Clifford; Pepin, Jacques; Wilcox, Mark H.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America (2010-05). "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)". Infection Control and Hospital Epidemiology. 31 (5): 431–455. doi:10.1086/651706. ISSN 1559-6834. PMID 20307191. Check date values in: |date= (help)
  13. Surawicz, Christina M.; Brandt, Lawrence J.; Binion, David G.; Ananthakrishnan, Ashwin N.; Curry, Scott R.; Gilligan, Peter H.; McFarland, Lynne V.; Mellow, Mark; Zuckerbraun, Brian S. (2013-04). "Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections". The American Journal of Gastroenterology. 108 (4): 478–498, quiz 499. doi:10.1038/ajg.2013.4. ISSN 1572-0241. PMID 23439232. Check date values in: |date= (help)
  14. Rebmann, Terri; Carrico, Ruth M.; Association for Professionals in Infection Control and Epidemiology, null (2011-04). "Preventing Clostridium difficile infections: an executive summary of the Association for Professionals in Infection Control and Epidemiology's elimination guide". American Journal of Infection Control. 39 (3): 239–242. doi:10.1016/j.ajic.2010.10.011. ISSN 1527-3296. PMID 21371783. Check date values in: |date= (help)
  15. Ferrada, Paula; Velopulos, Catherine G.; Sultan, Shahnaz; Haut, Elliott R.; Johnson, Emily; Praba-Egge, Anita; Enniss, Toby; Dorion, Heath; Martin, Niels D.; Bosarge, Patrick; Rushing, Amy; Duane, Therese M. (2014-06). "Timing and type of surgical treatment of Clostridium difficile-associated disease: a practice management guideline from the Eastern Association for the Surgery of Trauma". The Journal of Trauma and Acute Care Surgery. 76 (6): 1484–1493. doi:10.1097/TA.0000000000000232. ISSN 2163-0763. PMID 24854320. Check date values in: |date= (help)
  16. Steele, Scott R.; McCormick, James; Melton, Genevieve B.; Paquette, Ian; Rivadeneira, David E.; Stewart, David; Buie, W. Donald; Rafferty, Janice (2015-01). "Practice parameters for the management of Clostridium difficile infection". Diseases of the Colon and Rectum. 58 (1): 10–24. doi:10.1097/DCR.0000000000000289. ISSN 1530-0358. PMID 25489690. Check date values in: |date= (help)
  17. Debast, S. B.; Bauer, M. P.; Kuijper, E. J.; European Society of Clinical Microbiology and Infectious Diseases (2014-03). "European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection". Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 20 Suppl 2: 1–26. doi:10.1111/1469-0691.12418. ISSN 1469-0691. PMID 24118601. Check date values in: |date= (help)
  18. Schutze, Gordon E.; Willoughby, Rodney E.; Committee on Infectious Diseases; American Academy of Pediatrics (2013-01). "Clostridium difficile infection in infants and children". Pediatrics. 131 (1): 196–200. doi:10.1542/peds.2012-2992. ISSN 1098-4275. PMID 23277317. Check date values in: |date= (help)